This finding suggests that lncRNA DUXAP8 can improve treatment efficacy in progressive HCC patients by inhibiting the depalmitoylation of SLC7A11 and reducing its degradation to prevent ferroptosis. This evidence concerns the gene DUXAP8 and hepatocellular carcinoma.